Ms. Sylvia Cheung, CFO sylvia.cheung@oculis.com The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which was filed with the U.S. Securities and Exchange Commission along with a prospectus supplement. Please refer to the Company's SEC filings here and here, each dated May 8, 2024, for more details. These filings can be accessed through the Company's website. For more information, please visit: http: ...

Oculis Holding AG Unaudited Condensed Consolidated Interim Financial Statements Table of Contents | Unaudited Condensed Consolidated Interim: | | | --- | --- | | Statements of Financial Position as of March 31, 2024 and December 31, 2023 | 3 | | Statements of Loss for the three months ended March 31, 2024 and 2023 | 4 | | Statements of Comprehensive Loss for the three months ended March 31, 2024 and 2023 | 5 | | Statements of Changes in Equity for the three months ended March 31, 2024 and 2023 | 6 | | State ...

Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF trial in Dry Eye Disease (DED); RELIEF topline results anticipated in Q2 2024Completed $59 million registered direct equity offering and concurrent listing on Nasdaq Iceland Main Market in April 2024, extending cash runway into the second half of 2026Strengthened executive leadership team and U.S. presence with ...

ZUG, Switzerland, and BOSTON, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company") a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis' management will be attending and presenting at the Bank of America Healthcare Conference taking place on May 14-16, 2024 in Las Vegas, NV. Riad Sherif, M.D., Chief Executive Officer of Oculis, will deliver a company presentation on Wednesday, May 15th ...

ZUG, Switzerland, April 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) ("Oculis"), today published the invitation to the 2024 Annual General Meeting, which will be held on 29 May 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST / 9:30 a.m. EDT. All information pertaining to the 2024 Annual General Meeting, including meeting materials, can be accessed on the Oculis website at https://investors.oculis.com‌/events-presentations. About Oculis Oculis is a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

Oculis Holding AG Consolidated Financial Statements Table of Contents | Report of the Statutory auditor on the 2023 Consolidated Financial Statements | | | --- | --- | | Consolidated Statements of Financial Position as of December 31, 2023 and 2022 | 1 | | Consolidated Statements of Loss for the years ended December 31, 2023, 2022 and 2021 | 2 | | Consolidated Statements of Comprehensive Loss for the years ended December 31, 2023, 2022 and 2021 | 3 | | Consolidated Statements of Changes in Equity for the ye ...

Exhibit 99.1 Oculis Holding AG Unaudited Condensed Consolidated Interim Financial Statements Table of Contents Unaudited Condensed Consolidated Interim: | Statements of Financial Position as of September 30, 2023 and December 31, 2022 | 3 | | --- | --- | | Statements of Loss for the three and nine months ended September 30, 2023 and 2022 | 4 | | Statements of Comprehensive Loss for the three and nine months ended September 30, 2023 and 2022 | 5 | | Statements of Changes in Equity for the nine months ended S ...

Exhibit 99.1 Oculis Holding AG Unaudited Condensed Consolidated Interim Financial Statements Table of Contents Unaudited Condensed Consolidated Interim: | Statements of Loss for the three and six months ended June 30, 2023 and 2022 | 3 | | --- | --- | | Statements of Comprehensive Loss for the three and six months ended June 30, 2023 and 2022 | 4 | | Statements of Financial Position as of June 30, 2023 and December 31, 2022 | 5 | | Statements of Changes in Equity for the six months ended June 30, 2023 and 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...